Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Receivables (2022 - 2025)

Verrica Pharmaceuticals (VRCA) has 4 years of Receivables data on record, last reported at $5.3 million in Q4 2025.

  • For Q4 2025, Receivables rose 6731.17% year-over-year to $5.3 million; the TTM value through Dec 2025 reached $5.3 million, up 6731.17%, while the annual FY2025 figure was $5.3 million, 6731.17% up from the prior year.
  • Receivables reached $5.3 million in Q4 2025 per VRCA's latest filing, down from $7.0 million in the prior quarter.
  • Across five years, Receivables topped out at $10.2 million in Q2 2024 and bottomed at $77000.0 in Q4 2024.
  • Average Receivables over 4 years is $4.9 million, with a median of $5.3 million recorded in 2025.
  • Peak YoY movement for Receivables: tumbled 98.26% in 2024, then skyrocketed 8233.33% in 2025.
  • A 4-year view of Receivables shows it stood at $99000.0 in 2022, then skyrocketed by 4360.61% to $4.4 million in 2023, then crashed by 98.26% to $77000.0 in 2024, then surged by 6731.17% to $5.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $5.3 million in Q4 2025, $7.0 million in Q3 2025, and $9.2 million in Q2 2025.